Hard-to-detect prostate cancer may grow through cancer-stroma KRAS signaling

AI Summary

Researchers at Kanazawa University have identified a new molecular mechanism involving KRAS signaling that contributes to the progression of a treatment-resistant form of prostate cancer known as double-negative castration-resistant prostate cancer (DNPC). This discovery may aid in developing future therapies for this difficult-to-detect cancer type.

A research team at Kanazawa University, led by Professor Atsushi Mizokami, Associate Professor Koji Izumi and Specially Appointed Assistant Professor Taiki Kamishima (a fourth-year doctoral student at the Graduate School of Medical Sciences), has elucidated a novel molecular mechanism driving the progression of "double-negative castration-resistant prostate cancer (DNPC)"—one of the most treatment-resistant forms of prostate cancer.